Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Food Hypersensitivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Food Hypersensitivity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-001863-38 Sponsor Protocol Number: iFAAM-PPIwalnut Start Date*: 2015-09-24
    Sponsor Name:Fundación para la investigación biomedica del hospital clinico san carlos de madrid
    Full Title: The impact of proton-pump inhibitors (antacids) on threshold dose distributions
    Medical condition: walnut allergic patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011737-27 Sponsor Protocol Number: BASALIT Start Date*: 2010-01-07
    Sponsor Name:University Leipzig
    Full Title: A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic der...
    Medical condition: Immediate type allergy to soy proteins in patients with birch pollinosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021428 - Immune system disorders 10057630 Protein allergy LLT
    13.1 10021428 - Immune system disorders 10066093 Birch pollen allergy LLT
    13.1 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005060-18 Sponsor Protocol Number: 2016AL002 Start Date*: 2018-03-09
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blin...
    Medical condition: Determination of the Lowest Observed Adverse Event level dose (LOAEL)of peanut in individual suffering with peanut allergy, after treatment with allopurinol.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001738 Allergy LLT
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-000631-92 Sponsor Protocol Number: CQGE031A2208 Start Date*: 2011-12-07
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and olde...
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10034202 Peanut allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005038-53 Sponsor Protocol Number: FIM-PRU-2018-01 Start Date*: 2019-05-16
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS)
    Full Title: Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP w...
    Medical condition: LTP syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003627-30 Sponsor Protocol Number: 20170367744 Start Date*: 2018-06-27
    Sponsor Name:Odense Research Center for Anaphylaxis (ORCA)
    Full Title: Protection from food induced anaphylaxis by reducing serum level of specific IgE
    Medical condition: Food Allergy with Anaphylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10014315 Egg allergy LLT
    20.0 100000004870 10016709 Fish allergy LLT
    20.0 100000004870 10040539 Shellfish allergy LLT
    20.0 100000004870 10001745 Allergy to cow's milk LLT
    20.1 100000004870 10034202 Peanut allergy LLT
    20.0 100000004870 10027024 Meat allergy LLT
    20.0 100000004870 10011240 Cow's milk allergy LLT
    20.1 100000004870 10054957 Allergy to grains LLT
    20.1 100000004870 10054959 Allergy to nuts LLT
    20.0 100000004870 10064075 Seafood allergy LLT
    20.0 100000004870 10076438 Milk protein allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003019-39 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study
    Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001738 Allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000276-10 Sponsor Protocol Number: FAST2015 Start Date*: 2015-07-02
    Sponsor Name:FAST Consortium under EU 7. FWP
    Full Title: FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single ri...
    Medical condition: Food allergy to fish
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed) DK (Completed) GR (Ongoing) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000326-58 Sponsor Protocol Number: ARC009 Start Date*: 2018-09-27
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real-World, Open-Label, Quality of Life Study
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002461-37 Sponsor Protocol Number: PEPITES Start Date*: 2015-12-17
    Sponsor Name:DBV Technologies
    Full Title: A double-blind, placebo-controlled, randomized phase III pivotal trial to assess the efficacy and safety of peanut epicutaneous immunotherapy with viaskin peanut in peanut-allergic children
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003323-10 Sponsor Protocol Number: V712-305(EPOPEX) Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000868-29 Sponsor Protocol Number: V712-101 Start Date*: 2021-10-25
    Sponsor Name:DBV Technologies S.A.
    Full Title: Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase I Safety Study in Adult and Pediatric Subjects
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002916-42 Sponsor Protocol Number: PEOPLE-V712-303 Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin® Peanut (PEOPLE Study)
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001754-10 Sponsor Protocol Number: OLFUS-VIPES Start Date*: 2014-02-24
    Sponsor Name:DBV Technologies S.A
    Full Title: Open-label follow-up study of the VIPES study to evaluate long-term efficacy and safety of the Viaskin Peanut
    Medical condition: Treatment of peanut allergy in adults and children age 7 years and older with documented hypersensitivity to peanut. The induction of clinical desensitization to peanut in patients allergic to pean...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006950-30 Sponsor Protocol Number: CLOU064I12201 Start Date*: 2022-08-02
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005339-56 Sponsor Protocol Number: CQGE031G12301 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients wi...
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001334-26 Sponsor Protocol Number: ARC008 Start Date*: 2018-01-17
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended) SE (Completed) ES (Completed) DE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002031-26 Sponsor Protocol Number: RHMCHI065 Start Date*: 2013-06-25
    Sponsor Name:University Hospitals Southampton NHS Foundation Trust
    Full Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE study
    Medical condition: Children aged 24 months to (and including) 17 years with IgE-mediated food allergy to egg protein
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10014315 Egg allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001749-15 Sponsor Protocol Number: ARC005 Start Date*: 2019-05-21
    Sponsor Name:Aimmune Therapeutics , Inc.
    Full Title: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002550-32 Sponsor Protocol Number: VIPES Start Date*: 2012-12-21
    Sponsor Name:DBV Technologies SA
    Full Title: A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults.
    Medical condition: Treatment of peanut allergy in adults and children age 6 years and older with documented hypersensitivity to peanut. The induction of clinical desensitization to peanut in patients allergic to pean...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA